Andres Oliver, Eber Stefan, Speer Christian P
University Children's Hospital, University of Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.
Technical University Children's Hospital, Waldfriedhofstraße 73, 81377, Munich, Germany.
Ann Hematol. 2015 Dec;94(12):1959-64. doi: 10.1007/s00277-015-2491-z. Epub 2015 Sep 4.
Exact diagnosis of hereditary spherocytosis (HS) is widely considered unreliable around birth. However, early postnatal diagnosis at the beginning of congenital hemolysis may be essential for managing neonatal anemia and hemolytic icterus, identifying those at high risk for severe hyperbilirubinemia, irreversible kernicterus, or sudden need for red cell transfusion. We analyzed 37 blood samples from neonates or infants up to six weeks of life that had been collected in-house or shipped to our laboratory due to suspected red cell membrane disorder. By combining assessment of red cell morphology, acidified glycerol lysis test (AGLT), and eosin-5'-maleimide (EMA) binding assay, we were able to clearly exclude HS in 22 and confirm HS in 10 patients, of which one had undergone red cell transfusion prior to blood sampling. Assessment of red cell morphology and normal test results allowed diagnosis of infantile pyknocytosis or Heinz body anemia in three neonates. Re-evaluation of five patients with inconsistent results of AGLT and EMA binding led to confirmation of HS in two cases. Automated analysis of hematologic parameters revealed elevated proportion of hyperdense cells to be a highly significant indicator for HS in neonatal infants. We showed that assessment of red cell morphology in combination with AGLT and EMA binding assay is a reliable basis for confirming or rejecting suspected diagnosis of HS even in neonates. Our data underline the necessity for blood sampling and laboratory exploration in suspected red cell membrane or enzyme defects at the earliest occasion.
遗传性球形红细胞增多症(HS)在出生时的准确诊断普遍被认为不可靠。然而,在先天性溶血开始时进行出生后早期诊断对于管理新生儿贫血和溶血性黄疸、识别那些有严重高胆红素血症、不可逆核黄疸或突然需要红细胞输血高风险的患者可能至关重要。我们分析了37份来自新生儿或6周龄以内婴儿的血样,这些血样是在内部采集的,或者因怀疑红细胞膜疾病而被送到我们实验室的。通过结合红细胞形态评估、酸化甘油溶解试验(AGLT)和嗜酸性-5'-马来酰亚胺(EMA)结合试验,我们能够明确排除22例HS,并确诊10例HS患者,其中1例在采血前接受过红细胞输血。红细胞形态评估和正常检测结果使我们诊断出3例新生儿的婴儿型致密红细胞症或海因茨小体贫血。对5例AGLT和EMA结合结果不一致的患者进行重新评估后,确诊2例HS。血液学参数的自动分析显示,高密度细胞比例升高是新生儿HS的一个高度显著指标。我们表明,即使在新生儿中,结合AGLT和EMA结合试验对红细胞形态进行评估也是确认或排除疑似HS诊断的可靠依据。我们的数据强调了在怀疑存在红细胞膜或酶缺陷时尽早进行采血和实验室检查的必要性。